This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read the article by Winkelman et al. with interest.1 We noted that every author in this review works for or receives money from Boehringer Ingelheim Pharmaceuticals, Inc. In their abstract, the authors make the following conclusion: “As rated by patients and by clinicians, pramipexole was efficacious and safe in reducing the symptoms of restless legs syndrome.” While we do not dispute that the data imply that pramipexole may have a role in the treatment of restless legs syndrome (RLS), we have several concerns.
The authors listed adverse events (AEs) in table 2. The “safety” that the authors describe is not affirmed when 50.8% of those receiving pramipexole (all doses; compared to 31.4% for placebo) had AEs, including about 37% more of those rated to be severe in intensity.
Less frequently occurring AEs are not reported. We would be interested to learn of neuropsychiatric AEs (e.g., dyskinesia, hallucinations, mood alterations, psychotic reactions), similar to those reported in the US Food and Drug Administration (FDA)–approved product label for pramipexole (as Mirapex).
Secondly, a concern to both the authors and to us was the exceptionally high placebo rate. In the Results …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.